Recruiting PHASE2/PHASE3 INTERVENTIONAL 8-arm NCT05255653

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features (RAINBO)

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features: the P53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial

Sponsor: AstraZeneca

Conditions Endometrial Cancer

Interventions Chemotherapy Durvalumab Medroxyprogesterone Acetate Megestrol Acetate Observation Olaparib Pelvic external beam radiotherapy Vaginal brachytherapy

Updated 10 times since 2022 Last updated: Nov 26, 2024 Started: Nov 11, 2021 Primary completion: Jan 1, 2030 Completion: Jan 1, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Endometrial Cancer, this trial is actively recruiting participants. The trial is conducted by AstraZeneca and has accumulated 10 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2/PHASE3
Dec 2024 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Aug 2023 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 5 earlier versions

May 2023 — Aug 2023 [monthly]

Recruiting PHASE2_PHASE3
Nov 2022 — May 2023 [monthly]

Recruiting PHASE2_PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
May 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3
Mar 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial)
Canadian Institutes of Health Research (CIHR)
Cancer Research UK & UCL Cancer Trials Centre
Comprehensive Cancer Centre The Netherlands
Dutch Cancer Society
Dutch Gynaecological Oncology Group
Institute Gustave Roussy (sponsor p53abn-RED trial)
Leiden University Medical Center
Leiden University Medical center (sponsor MMRd-GREEN trial)
National Cancer Institute, France
University College London (sponsor NSMP-ORANGE trial)

Data source: Leiden University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Breda, Netherlands , Eindhoven, Netherlands , Enschede, Netherlands , Groningen, Netherlands , Leiden, Netherlands , London, United Kingdom , Manchester, United Kingdom , Rotterdam, Netherlands , The Hague, Netherlands and 3 more locations